Cure8 research brief
This review highlights shared biomarkers and mechanisms between early Crohn's disease and post-operative recurrence, which could improve prediction and lead to preventive strategies for recurrence after surgery.
Patients with Crohn's disease (especially post-surgery), clinicians managing postoperative IBD care, and researchers studying biomarkers, the microbiome, or immune pathways in IBD.
This paper reviews recent biomarker and multi-omics studies comparing early (preclinical) Crohn's disease with the period immediately after ileocolonic resection, when patients are temporarily disease-free.
The authors report overlapping predictive signatures including genetic variants, immune mediators (for example CXCL9 and IL-6), microbial taxa (such as Faecalibacterium and Ruminococcus), and markers of barrier dysfunction and systemic inflammation.
The review highlights emerging approaches—glycomics, urine metabolomics, and high-dimensional immunophenotyping—that may improve risk stratification and clarify host–microbe–immune mechanisms.
The authors propose the post-operative period as a pragmatic human model to test biomarker-guided preventive interventions that could apply to both disease prevention and recurrence reduction.
This is a narrative review synthesizing biomarker and multi-omics studies; proposed intervention strategies are conceptual and require prospective testing.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
The study identifies colonic gene-expression programs that correlate with treatment failure, higher surgery rates, and perianal disease in Crohn’s — findings that could guide future prognostic tests and targeted...
This narrative review surveys novel biomarkers and therapeutic strategies for adult IBD, topics that could affect diagnosis, monitoring, and future treatment options for people with Crohn's disease or ulcerative colitis.
Researchers are investigating circRNAs as potential biomarkers and therapeutic targets in IBD because they may help explain disease mechanisms and lead to better diagnostics or treatments in the future.
